# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000886163-25-000027
Filing Date
2025-04-22
Accepted
2025-04-22 16:09:42
Documents
4

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | ligand-2025proxysupplement.htm | DEFA14A | 9797
2 |  | newligandlogo.jpg | GRAPHIC | 43732
3 |  | notice1of2.jpg | GRAPHIC | 458857
4 |  | notice2of2.jpg | GRAPHIC | 349751
| Complete submission text file | 0000886163-25-000027.txt |  | 1184804

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33093 | Film No.: 25857822
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)